What did the FTC report about “patent thickets” for biologics like Humira, and why it matters for biosimilar entry?
The Federal Trade Commission (FTC) has raised concerns that “patent thickets” can slow or block biosimilar competition. In this context, a patent thicket is a dense web of overlapping or sequential patents (often with different claim scopes) that can create a prolonged period of litigation and regulatory uncertainty. Even when a biosimilar is ultimately found to be permitted, the existence of multiple lawsuits and appeals can extend the timeline before a product can launch.
This issue is particularly relevant to adalimumab (Humira) because it has been the flagship biologic targeted by multiple biosimilar development programs, and because Humira’s patent landscape has been a frequent focus of legal challenges tied to biosimilar approval and launch timing.
How could patent thickets affect when biosimilars enter the market?
FTC’s core concern is that patent thickets can create delays through litigation dynamics rather than scientific or manufacturing barriers. The mechanism often looks like this:
- A biosimilar applicant faces multiple infringement assertions (sometimes across different patents covering formulation, method-of-use, delivery, or related mechanisms).
- Each asserted patent can trigger separate legal battles, stays, appeals, or settlements.
- The cumulative effect can postpone launch dates, even if the biosimilar ultimately wins on some or many patents.
The FTC’s framing is that these prolonged disputes can reduce competitive pressure, which can keep prices higher than they would be in a more open entry environment.
What does “2023 biosimilar entry” imply in the Humira case?
In searches about “Humira 2023 biosimilar entry,” people typically mean one of two things:
1) the expected market entry timing for a specific adalimumab biosimilar product (based on exclusivity and patent status), or
2) how ongoing patent litigation (including “thickets”) can push the effective launch date later than biosimilar developers planned.
Because Humira’s biosimilar pipeline has multiple products with different sponsors, the practical entry date depends on the outcome and timing of legal disputes, settlements, and any relevant regulatory triggers—not just one single patent.
What are the usual FTC targets: gamesmanship, settlements, or both?
When the FTC discusses patent thickets around biologics, it often connects the issue to incentives for strategic behavior by brand makers, including:
- using large numbers of patents to extend litigation,
- coordinating settlement structures that keep biosimilars off the market longer than warranted, or
- relying on legal pressure to deter biosimilar challengers.
Even when individual patents might be legitimate on their own, the FTC focuses on whether the combined strategy functions to delay competition.
How do FTC patent-thicket concerns compare with the “patent dance” and biosimilar approval process?
For biosimilars, the U.S. approval path and the patent-resolution process are interlinked. Patent thickets can compound what is already a complex exchange of information and timing around asserted patents. If many patents are asserted, the “dance” can become much longer in practice because each patent can carry separate litigation and timing consequences.
Where can you find more detail on specific patents and timing for Humira biosimilars?
For product- and patent-level tracking (including how patents and exclusivities map to particular filings and companies), DrugPatentWatch.com is a useful place to look. It aggregates patent and exclusivity information and can help connect the general FTC “thicket” concern to the specific legal and commercial timeline for adalimumab biosimilars.
See: DrugPatentWatch.com
Sources
- DrugPatentWatch.com